Teva Has Grand Ambitions In Respiratory Disease, With An Eye On Advair
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva expects to more than double its respiratory sales to $2.4 billion by 2015, and launch multiple products in the timeframe, including an Advair-like product.
You may also be interested in...
Teva's AirDuo Authorized Generic Priced At A 70% Discount To Advair
Teva's decision to launch an authorized generic version of AirDuo, a drug made up of the same active ingredients in GSK's Advair, at a steep discount to typical brand drugs for asthma will help encourage use, even though it is not interchangeable.
Teva's AirDuo Authorized Generic Priced At A 70% Discount To Advair
Teva's decision to launch an authorized generic version of AirDuo, a drug made up of the same active ingredients in GSK's Advair, at a steep discount to typical brand drugs for asthma will help encourage use, even though it is not interchangeable.
Teva AirDuo Poised To Be A Discounted, But Not Interchangeable, Version Of Advair
FDA approved Teva’s AirDuo RespiClick, which contains the active ingredients in GlaxoSmithKline’s Advair, but in the RespiClick device, which means it will not be an interchangeable generic.